Amedeo Smart

Free Medical Literature Service

 

Amedeo

Otorhinolaryngology
  Free Subscription

Articles published in
Radiother Oncol
    April 2024
  1. FITZGERALD KT, Lyons C, England A, McEntee MF, et al
    Risk factors associated with the development of osteoradionecrosis (ORN) in Head and Neck cancer patients in Ireland: A 10-year retrospective review.
    Radiother Oncol. 2024 Apr 17:110286. doi: 10.1016/j.radonc.2024.110286.
    >> Share

  2. ZHENG Z, Shen Y, Su J, Ji X, et al
    Assessing radiation-induced carotid artery injury using ultrasound in patients with head and neck cancer.
    Radiother Oncol. 2024 Apr 17:110285. doi: 10.1016/j.radonc.2024.110285.
    >> Share

  3. CHEN AM, Harris JP, Nabar R, Tjoa T, et al
    Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer.
    Radiother Oncol. 2024 Apr 16:110278. doi: 10.1016/j.radonc.2024.110278.
    >> Share

  4. DE LEEUW ALMP, Giralt J, Tao Y, Benavente S, et al
    A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).
    Radiother Oncol. 2024 Apr 16:110281. doi: 10.1016/j.radonc.2024.110281.
    >> Share

  5. SHUANG H, Feng J, Caineng C, Qifeng J, et al
    Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study.
    Radiother Oncol. 2024 Apr 5:110265. doi: 10.1016/j.radonc.2024.110265.
    >> Share

  6. CHOW JCH, Lee J, Lai MMP, Li S, et al
    Multi-domain neurocognitive impairment following definitive intensity-modulated radiotherapy for nasopharyngeal cancer: A cross-sectional study.
    Radiother Oncol. 2024;193:110143.
    >> Share

    March 2024
  7. DONG J, Ng WT, Wong CHL, Li JS, et al
    Dosimetric parameters predict radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma patients: A systematic review and meta-analysis.
    Radiother Oncol. 2024 Mar 25:110258. doi: 10.1016/j.radonc.2024.110258.
    >> Share

  8. HUYNH TM, Falk RS, Hellebust TP, Dale E, et al
    Chronic fatigue in long-term survivors of head and neck cancer treated with radiotherapy.
    Radiother Oncol. 2024;195:110231.
    >> Share

  9. BERTHOLET J, Mackeprang PH, Loebner HA, Mueller S, et al
    Organs-at-risk dose and normal tissue complication probability with dynamic trajectory radiotherapy (DTRT) for head and neck cancer.
    Radiother Oncol. 2024 Mar 19:110237. doi: 10.1016/j.radonc.2024.110237.
    >> Share

  10. BOON CS, Ramkumar S, Boon IS
    Proton beam radiotherapy head and neck cancer study design and endpoints.
    Radiother Oncol. 2024 Mar 16:110234. doi: 10.1016/j.radonc.2024.110234.
    >> Share

  11. KOUTROUMPAKIS E, Mohamed ASR, Chaftari P, Rosenthal DI, et al
    Longitudinal changes in the carotid arteries of head and neck cancer patients following radiation therapy: Results from a prospective serial imaging biomarker characterization study.
    Radiother Oncol. 2024 Mar 9:110220. doi: 10.1016/j.radonc.2024.110220.
    >> Share

  12. CHOW JCH, Ho JCS, Man Cheung K, Johnson D, et al
    Neurological complications of modern radiotherapy for head and neck cancer.
    Radiother Oncol. 2024 Mar 2:110200. doi: 10.1016/j.radonc.2024.110200.
    >> Share

  13. CARSUZAA F, Chary E, Thariat J, Dufour X, et al
    Obstructive sleep apnea syndrome: A frequent and difficult-to-detect complication of radiotherapy for oropharyngeal cancers.
    Radiother Oncol. 2024;192:110109.
    >> Share

  14. ZHANG WW, Lin JY, Wang GY, Huang CL, et al
    Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
    Radiother Oncol. 2024;194:110189.
    >> Share

    February 2024
  15. POPULAIRE P, Defraene G, Haustermans K
    Letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbee et al.
    Radiother Oncol. 2024 Feb 28:110175. doi: 10.1016/j.radonc.2024.110175.
    >> Share

  16. KOTO M, Ikawa H, Inaniwa T, Imai R, et al
    Dose-averaged LET optimized carbon-ion radiotherapy for head and neck cancers.
    Radiother Oncol. 2024;194:110180.
    >> Share

  17. BERBEE M, Muijs CT, Schuit E
    Response to letter to the editor regarding "External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts" by M. Berbee et al.
    Radiother Oncol. 2024 Feb 17:110176. doi: 10.1016/j.radonc.2024.110176.
    >> Share

  18. FIORINO C, Palumbo D, Mori M, Palazzo G, et al
    Early regression index (ERI) on MR images as response predictor in esophageal cancer treated with neoadjuvant chemo-radiotherapy: Interim analysis of the prospective ESCAPE trial.
    Radiother Oncol. 2024;194:110160.
    >> Share

  19. WANG X, Huang N, Yip PL, Wang J, et al
    The individualized delineation of clinical target volume for primary nasopharyngeal carcinoma based on invasion risk of substructures: A prospective, real-word study with a large population.
    Radiother Oncol. 2024;194:110154.
    >> Share

  20. HORSHOLT KRISTENSEN M, Kristina Sorensen M, Tramm T, Alsner J, et al
    Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - a DAHANCA 19 study.
    Radiother Oncol. 2024 Feb 8:110149. doi: 10.1016/j.radonc.2024.110149.
    >> Share

  21. PERRIER L, Balusson F, Morelle M, Castelli J, et al
    Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial.
    Radiother Oncol. 2024;193:110116.
    >> Share

    January 2024
  22. FRANK MH, van Dijk BAC, Schoonbeek RC, Zindler J, et al
    Differences in the association of time to treatment initiation and survival according to various head and neck cancer sites in a nationwide cohort.
    Radiother Oncol. 2024 Jan 21:110107. doi: 10.1016/j.radonc.2024.110107.
    >> Share

  23. BLITZER GC, Paz C, Glassey A, Ganz OR, et al
    Functionality of Bone Marrow Mesenchymal Stromal Cells Derived from Head and Neck Cancer Patients - A FDA-IND Enabling Study Regarding MSC-based Treatments for Radiation-Induced Xerostomia.
    Radiother Oncol. 2024 Jan 13:110093. doi: 10.1016/j.radonc.2024.110093.
    >> Share

  24. PIERIK AS, Poell JB, Brink A, Stigter-van Walsum M, et al
    Intratumor genetic heterogeneity and head and neck cancer relapse.
    Radiother Oncol. 2024 Jan 5:110087. doi: 10.1016/j.radonc.2024.110087.
    >> Share

  25. WANG F, Zhou L, Zhang LJ, Xie CB, et al
    Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy: a propensity score-matched cohort study.
    Radiother Oncol. 2024 Jan 5:110081. doi: 10.1016/j.radonc.2024.110081.
    >> Share

  26. GUO Q, Lu T, Huang W, Xu H, et al
    Selectively sparing of the supraclavicular area during intensity-modulated radiotherapy in nasopharyngeal carcinoma: A double-center observation study.
    Radiother Oncol. 2024 Jan 4:110086. doi: 10.1016/j.radonc.2024.110086.
    >> Share

  27. VERDUIJN GM, Sijtsema ND, van Norden Y, Heemsbergen WD, et al
    Response to the letter-to-the-editor "Comments on: Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment".
    Radiother Oncol. 2024;190:110036.
    >> Share

  28. SOMAY E, Yilmaz B, Topkan E
    Comments on "Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment".
    Radiother Oncol. 2024;190:110035.
    >> Share

  29. ZHU Y, Cheng J, Li Y, Pan D, et al
    Progression of cognitive dysfunction in NPC survivors with radiation-induced brain necrosis: A prospective cohort.
    Radiother Oncol. 2024;190:110033.
    >> Share

    December 2023
  30. MURDAUGH DL, Milner D, Cardenas CE, Heinzman KA, et al
    Volumetric Brain Assessment of Long-Term Head and Neck Cancer Survivors.
    Radiother Oncol. 2023 Dec 22:110068. doi: 10.1016/j.radonc.2023.110068.
    >> Share

  31. LIN CY, Chang CL, Lin KC, Chen WM, et al
    Statin Use Reduces Radiation-Induced Stroke Risk in Advanced Nasopharyngeal Carcinoma Patients.
    Radiother Oncol. 2023 Dec 22:110067. doi: 10.1016/j.radonc.2023.110067.
    >> Share

  32. YU-CHEN, Luo MJ, Liu RP, Jin J, et al
    Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Dec 20:110051. doi: 10.1016/j.radonc.2023.110051.
    >> Share

  33. AI QYH, King AD, Yuan H, Vardhanabhuti V, et al
    Radiologic extranodal extension for nodal staging in nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Dec 13:110050. doi: 10.1016/j.radonc.2023.110050.
    >> Share

  34. BIRD D, Speight R, Andersson S, Wingqvist J, et al
    Deep learning MRI-only synthetic-CT generation for pelvis, brain and head and neck cancers.
    Radiother Oncol. 2023 Dec 12:110052. doi: 10.1016/j.radonc.2023.110052.
    >> Share

  35. HABRICH J, Boeke S, Fritz V, Koerner E, et al
    Reproducibility of diffusion-weighted magnetic resonance imaging in head and neck cancer assessed on a 1.5 T MR-Linac and comparison to parallel measurements on a 3 T diagnostic scanner.
    Radiother Oncol. 2023 Dec 7:110046. doi: 10.1016/j.radonc.2023.110046.
    >> Share

  36. MARIA HUYNH TT, Dale E, Sorum Falk R, Paulsen Hellebust T, et al
    Radiation-induced long-term dysphagia in survivors of head and neck cancer and association with dose-volume parameters.
    Radiother Oncol. 2023 Dec 5:110044. doi: 10.1016/j.radonc.2023.110044.
    >> Share

  37. HOU Z, Guo Y, Shen X, Dong B, et al
    Treatment options for stage III-N2 pulmonary lymphoepithelioma-like carcinoma: A retrospective cohort study.
    Radiother Oncol. 2023;189:109937.
    >> Share

    November 2023
  38. MENG Z, Li P, Yang D, Huang H, et al
    The feasibility of level Ib-sparing intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma and high-risk factors classified based on the International Guideline.
    Radiother Oncol. 2023 Nov 24:110027. doi: 10.1016/j.radonc.2023.110027.
    >> Share

  39. SOMAY E, Topkan E, Selek U
    Comment on: The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
    Radiother Oncol. 2023 Nov 24:110025. doi: 10.1016/j.radonc.2023.110025.
    >> Share

  40. BUURMAN DJM, Speksnijder CM, Granzier ME, Timmer VCML, et al
    Response to: Comment on: The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
    Radiother Oncol. 2023 Nov 24:110026. doi: 10.1016/j.radonc.2023.110026.
    >> Share

  41. DELERUE C, Pasquier D, Bogart E, Mirabel X, et al
    Stereotactic reirradiation in the treatment of head and neck cancers: A retrospective study on the long-term experience of the Oscar Lambret Center.
    Radiother Oncol. 2023;190:110029.
    >> Share

  42. HUANG CL, Wang GY, Lou JH, Chen L, et al
    Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up.
    Radiother Oncol. 2023;190:110032.
    >> Share

  43. BERBEE M, Muijs CT, Voncken FEM, Wee LS, et al
    External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts.
    Radiother Oncol. 2023 Nov 8:109979. doi: 10.1016/j.radonc.2023.109979.
    >> Share

  44. HR M, P P, L H, Ds M, et al
    PROton versus photon Therapy for Esophageal Cancer - a Trimodality strategy (PROTECT) NCT050555648.
    Radiother Oncol. 2023 Nov 5:109980. doi: 10.1016/j.radonc.2023.109980.
    >> Share

  45. CHEN L, Li J, Li K, Hu J, et al
    Evaluation and Analysis of Risk Factors of Hearing Impairment for Nasopharyngeal Carcinoma treated using Intensity-Modulated Radiotherapy.
    Radiother Oncol. 2023 Nov 3:109985. doi: 10.1016/j.radonc.2023.109985.
    >> Share

  46. KIM K, Oh D, Myoung Noh J, Won Min Y, et al
    Outcomes Following Hypofractionated Radiation Therapy Alone for Surgically Unfit Early Esophageal Squamous Cell Carcinoma Patients; A Retrospective Single Center Analysis.
    Radiother Oncol. 2023 Nov 3:109982. doi: 10.1016/j.radonc.2023.109982.
    >> Share

    October 2023
  47. HE YQ, Wang TM, Yang DW, Xue WQ, et al
    A comprehensive predictive model for radiation-induced brain injury in risk stratification and personalized radiotherapy of nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Oct 30:109974. doi: 10.1016/j.radonc.2023.109974.
    >> Share

  48. AMSTUTZ F, Krcek R, Bachtiary B, Weber DC, et al
    Treatment planning comparison for head and neck cancer between photon, proton, and combined proton-photon therapy - from a fixed beam line to an arc.
    Radiother Oncol. 2023 Oct 30:109973. doi: 10.1016/j.radonc.2023.109973.
    >> Share

  49. FRIBORG J, Jensen K, Eriksen JG, Samsoe E, et al
    Considerations for study design in the DAHANCA 35 trial of protons versus photons for head and neck cancer.
    Radiother Oncol. 2023 Oct 21:109958. doi: 10.1016/j.radonc.2023.109958.
    >> Share

  50. CHEN AM
    Management of Unknown Primary Head and Neck Cancer with Radiation Therapy in the Era of Human Papillomavirus (HPV): No Longer Cutting Down the Tree to Get an Apple.
    Radiother Oncol. 2023 Oct 14:109952. doi: 10.1016/j.radonc.2023.109952.
    >> Share

  51. GAI X, Su L, Huang S, Zeng J, et al
    Correlation between hippocampal radiation doses and psychological condition for patients with stage T1-2 nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Oct 7:109942. doi: 10.1016/j.radonc.2023.109942.
    >> Share

  52. LI S, Zhang W, Liang B, Huang W, et al
    A Rulefit-Based Prognostic Analysis Using Structured MRI Report to Select Potential Beneficiaries from Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: A Dual-Centre Study.
    Radiother Oncol. 2023 Oct 7:109943. doi: 10.1016/j.radonc.2023.109943.
    >> Share

  53. LIN CH, Yan JL, Yap WK, Kang CJ, et al
    Prognostic Value of Interim CT-based Peritumoral and Intratumoral Radiomics in Laryngeal and Hypopharyngeal Cancer Patients Undergoing Definitive Radiotherapy.
    Radiother Oncol. 2023 Oct 6:109938. doi: 10.1016/j.radonc.2023.109938.
    >> Share

  54. SUN XS, Wang JW, Han F, Zou RH, et al
    Prognostic value of metastatic cervical lymph node stiffness in nasopharyngeal carcinoma: A prospective cohort study.
    Radiother Oncol. 2023 Oct 6:109939. doi: 10.1016/j.radonc.2023.109939.
    >> Share

    September 2023
  55. YEONG SONG J, Sung Ho M, Suh YG, Kim JH, et al
    Definitive radiotherapy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: a multicenter retrospective study (KROG 21-10).
    Radiother Oncol. 2023 Sep 30:109936. doi: 10.1016/j.radonc.2023.109936.
    >> Share

  56. BOLLEN H, Gulyban A, Nuyts S
    Impact of consensus guidelines on delineation of primary tumor Clinical Target Volume (CTVp) for head and neck cancer: results of a national review project.
    Radiother Oncol. 2023 Sep 20:109915. doi: 10.1016/j.radonc.2023.109915.
    >> Share

  57. LIU S, Zou Y, Zhong M, Li T, et al
    Prognostic Significance of MRI-Defined Sarcopenia in Patients with Nasopharyngeal Carcinoma: A Propensity Score Matched Analysis of Real-World Data.
    Radiother Oncol. 2023 Sep 5:109904. doi: 10.1016/j.radonc.2023.109904.
    >> Share

  58. YAN W, Liu T, He M, Yi J, et al
    Induction chemotherapy plus re-irradiation versus re-irradiation alone in locally recurrent nasopharyngeal carcinoma: A model-based analysis.
    Radiother Oncol. 2023 Sep 5:109903. doi: 10.1016/j.radonc.2023.109903.
    >> Share

  59. ADRIAN G, Forslund O, Pedersen L, Sjovall J, et al
    Circulating tumour HPV16 DNA quantification - A prognostic tool for progression-free survival in patients with HPV-related oropharyngeal carcinoma receiving curative chemoradiotherapy.
    Radiother Oncol. 2023;186:109773.
    >> Share

  60. SIJTSEMA ND, Verduijn GM, Nasserinejad K, van Norden Y, et al
    Development of a local dose-response relationship for osteoradionecrosis within the mandible.
    Radiother Oncol. 2023;186:109736.
    >> Share

  61. LI D, Yang LN, Lin JY, Wu YZ, et al
    Eosinophil Dynamics During Chemo-Radiotherapy Correlate to Clinical Outcome in Stage ?-?a Nasopharyngeal Carcinoma Patients: Results from A Large Cohort Study.
    Radiother Oncol. 2023 Sep 1:109900. doi: 10.1016/j.radonc.2023.109900.
    >> Share

    August 2023
  62. OZER O, Shafi H, O'Reilly D, Loiseau C, et al
    Need for standardization in the use of structures in the intensity-modulated radiation therapy planning of head and neck cancers, a GORTEC study.
    Radiother Oncol. 2023 Aug 31:109895. doi: 10.1016/j.radonc.2023.109895.
    >> Share

  63. DING X, Cui X, Cui X, Wang S, et al
    Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: a meta-analysis.
    Radiother Oncol. 2023 Aug 23:109860. doi: 10.1016/j.radonc.2023.109860.
    >> Share

  64. ROESCH J, Ruhle A, Nicolay NH, Hecht M, et al
    Reply to the comment on "Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis'' by Kahvecioglu et al.
    Radiother Oncol. 2023 Aug 22:109866. doi: 10.1016/j.radonc.2023.109866.
    >> Share

  65. IYIZOBA-EBOZUE Z, Prestwich R, Brown S, Hall E, et al
    Neurocognitive function following (chemo)radiotherapy for nasopharyngeal cancer and other head and neck cancers: a systematic review.
    Radiother Oncol. 2023 Aug 22:109863. doi: 10.1016/j.radonc.2023.109863.
    >> Share

  66. KATSUTA T, Murakami Y, Kawahara D, Miyoshi S, et al
    Novel Simulation for Dosimetry Impact of Diaphragm Respiratory Motion in Four-Dimensional Volumetric Modulated Arc Therapy for Esophageal Cancer.
    Radiother Oncol. 2023 Aug 8:109849. doi: 10.1016/j.radonc.2023.109849.
    >> Share

  67. BUURMAN DJM, Speksnijder CM, Granzier ME, C M L Timmer V, et al
    The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer.
    Radiother Oncol. 2023 Aug 3:109847. doi: 10.1016/j.radonc.2023.109847.
    >> Share

  68. KOTEVSKI DP, Vajdic CM, Field M, Smee RI, et al
    Inter-hospital variation in data collection, radiotherapy treatment, and survival in patients with head and neck cancer: a multisite study.
    Radiother Oncol. 2023 Aug 3:109843. doi: 10.1016/j.radonc.2023.109843.
    >> Share

  69. DIAS GOMES DA SILVA N, Sergio da Silva Santos P, Carolina Magalhaes A, Afonso Rabelo Buzalaf M, et al
    Antibacterial, antibiofilm and anticaries effect of BioXtra(R) mouthrinse for head and neck cancer (HNC) patients under a microcosm biofilm model.
    Radiother Oncol. 2023 Aug 3:109846. doi: 10.1016/j.radonc.2023.109846.
    >> Share

    July 2023
  70. LIU J, Zhang B, Su Y, Qin G, et al
    Hypofractionated Radiotherapy compared with Conventionally Fractionated Radiotherapy to treat Initial Distant Metastases in Nasopharyngeal Carcinoma: A Multicenter, prospective, randomized, Phase II Trial.
    Radiother Oncol. 2023 Jul 20:109815. doi: 10.1016/j.radonc.2023.109815.
    >> Share

  71. HANSEN CR, Jensen K, Smulders B, Holm AIS, et al
    Evaluation of decentralised model-based selection of head and neck cancer patients for a proton treatment study. DAHANCA 35.
    Radiother Oncol. 2023 Jul 19:109812. doi: 10.1016/j.radonc.2023.109812.
    >> Share

  72. KAHVECIOGLU A, Yuce Sari S, Yazici G
    Comments on ''Dose-escalated Re-irradiation Improves Outcome in Locally Recurrent Head and Neck Cancer - Results of a Large Multicenter Analysis''.
    Radiother Oncol. 2023 Jul 17:109809. doi: 10.1016/j.radonc.2023.109809.
    >> Share

  73. LIN C, Lu N, Liang JL, Guo J, et al
    Clinical treatment considerations in the intensity-modulated radiotherapy era for parotid lymph node metastasis in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Jul 7:109802. doi: 10.1016/j.radonc.2023.109802.
    >> Share

  74. CONTI A
    In regard to: "Dosimetric predictive factors for facial nerve paralysis after Cyberknife stereotactic radiotherapy for vestibular schwannomas: A single institution experience of 88 patients".
    Radiother Oncol. 2023 Jul 6:109796. doi: 10.1016/j.radonc.2023.109796.
    >> Share

  75. GEHIN W, Lassalle B, Salleron J, Anxionnat R, et al
    Response to the letter-to-the-editor "In regard to: Dosimetric predictive factors for facial nerve paralysis after Cyberknife stereotactic radiotherapy for vestibular schwannomas: A single institution experience of 88 patients".
    Radiother Oncol. 2023 Jul 6:109797. doi: 10.1016/j.radonc.2023.109797.
    >> Share

  76. WEISS Y, Chin L, Younas E, Guo K, et al
    Cine MRI-based Analysis of Intrafractional Motion in Radiation Treatment Planning of Head and Neck Cancer Patients.
    Radiother Oncol. 2023 Jul 4:109790. doi: 10.1016/j.radonc.2023.109790.
    >> Share

  77. LIN P, Holloway L, Min M, Lee M, et al
    Prognostic and predictive values of baseline and mid-treatment FDG-PET in oropharyngeal carcinoma treated with primary definitive (chemo)radiation and impact of HPV status: Review of current literature and emerging roles.
    Radiother Oncol. 2023;184:109686.
    >> Share

  78. DE JONG BA, Korevaar EW, Maring A, Werkman CI, et al
    Proton arc therapy increases the benefit of proton therapy for oropharyngeal cancer patients in the model based clinic.
    Radiother Oncol. 2023;184:109670.
    >> Share

  79. ZHOU J, Wu J, Wu G, Huang J, et al
    TBX18 knockdown sensitizes esophageal squamous cell carcinoma to radiotherapy by blocking the CHN1/RhoA axis.
    Radiother Oncol. 2023 Jul 1:109788. doi: 10.1016/j.radonc.2023.109788.
    >> Share

    June 2023
  80. KJEMS J, Elisabet Hakansson K, Andrup Kristensen C, Grau Eriksen J, et al
    The influence of tumor volume on the risk of distant metastases in head and neck squamous cell carcinomas.
    Radiother Oncol. 2023 Jun 27:109771. doi: 10.1016/j.radonc.2023.109771.
    >> Share

  81. LIN X, Guo Z, Lin S, Qiu Y, et al
    Transcriptional expression of radiation-induced early cortical morphological alterations and its association with radiation necrosis in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Jun 27:109770. doi: 10.1016/j.radonc.2023.109770.
    >> Share

  82. GAN Y, Langendijk JA, van der Schaaf A, van den Bosch L, et al
    An efficient strategy to select head and neck cancer patients for adaptive radiotherapy.
    Radiother Oncol. 2023 Jun 21:109763. doi: 10.1016/j.radonc.2023.109763.
    >> Share

  83. YANG Q, Xia L, Feng LF, Gong WJ, et al
    Multi-trajectories of health-related quality of life and their associated factors in patients with nasopharyngeal carcinoma: A longitudinal study.
    Radiother Oncol. 2023 Jun 12:109743. doi: 10.1016/j.radonc.2023.109743.
    >> Share

  84. ROJO-SANTIAGO J, Korevaar E, Perko Z, Both S, et al
    PTV-based VMAT vs. robust IMPT for Head-and-Neck Cancer: A probabilistic uncertainty analysis of clinical plan evaluation with the Dutch model-based selection.
    Radiother Oncol. 2023 Jun 8:109729. doi: 10.1016/j.radonc.2023.109729.
    >> Share

  85. CAMPO F, Iocca O, De Virgilio A, Mazzola F, et al
    Treatment of oropharyngeal squamous cell carcinoma: Is swallowing quality better after TORS or RT?
    Radiother Oncol. 2023;183:109547.
    >> Share

    May 2023
  86. KONG FF, Pan GS, Du CR, Ni MS, et al
    Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: a recursive partitioning risk stratification analysis.
    Radiother Oncol. 2023 May 25:109721. doi: 10.1016/j.radonc.2023.109721.
    >> Share

  87. MCDONALD BA, Salzillo T, Mulder S, Ahmed S, et al
    Prospective Evaluation of In Vivo and Phantom Repeatability and Reproducibility of Diffusion-Weighted MRI Sequences on 1.5T MRI-Linear Accelerator (MR-Linac) and MR Simulator Devices for Head and Neck Cancers.
    Radiother Oncol. 2023 May 19:109717. doi: 10.1016/j.radonc.2023.109717.
    >> Share

  88. LU T, Xu H, Huang W, Zong J, et al
    Constructing an Individualized Surveillance Framework for Nasopharyngeal Carcinoma Based on a Dynamic Risk-adapted Approach.
    Radiother Oncol. 2023 May 17:109716. doi: 10.1016/j.radonc.2023.109716.
    >> Share

  89. MORAL NAKAMURA D, da Graca Pinto H, Baena Elchin C, Thomazotti Berard L, et al
    Efficacy of bethanechol chloride in the treatment of radiation-induced xerostomia in patients with head and neck cancer: a systematic review and meta-analysis.
    Radiother Oncol. 2023 May 17:109715. doi: 10.1016/j.radonc.2023.109715.
    >> Share

  90. LU J, Qin Z, Li N, Ma J, et al
    High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: a systematic review and meta-analysis.
    Radiother Oncol. 2023 May 9:109700. doi: 10.1016/j.radonc.2023.109700.
    >> Share

  91. FENG ZONG J, Lin PJ, Tsou HH, Guo Q, et al
    Comparison the Acute Toxicity of Two Different Induction Chemotherapy Schedules with Cisplatin and Fluorouracil in Nasopharyngeal Carcinoma Patients.
    Radiother Oncol. 2023 May 9:109699. doi: 10.1016/j.radonc.2023.109699.
    >> Share

    April 2023
  92. ZHAO DW, Teng F, Meng LL, Fan WJ, et al
    Development and validation of a nomogram for prediction of recovery from moderate-severe xerostomia post-radiotherapy in nasopharyngeal carcinoma patients.
    Radiother Oncol. 2023 Apr 27:109683. doi: 10.1016/j.radonc.2023.109683.
    >> Share

  93. PAN Z, Men K, Liang B, Song Z, et al
    A subregion-based prediction model for local-regional recurrence risk in head and neck squamous cell carcinoma.
    Radiother Oncol. 2023 Apr 27:109684. doi: 10.1016/j.radonc.2023.109684.
    >> Share

  94. ZHAO W, Ke S, Cai X, Zuo Z, et al
    Radiotherapy plus camrelizumaband irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
    Radiother Oncol. 2023 Apr 25:109679. doi: 10.1016/j.radonc.2023.109679.
    >> Share

  95. A C FIAGAN Y, Bossuyt E, Nevens D, Machiels M, et al
    The use of in-vivo dosimetry to identify head and neck cancer patients needing adaptive radiotherapy.
    Radiother Oncol. 2023 Apr 19:109676. doi: 10.1016/j.radonc.2023.109676.
    >> Share

    March 2023
  96. BOLOGNA M, Corino V, Cavalieri S, Calareso G, et al
    Prognostic radiomic signature for head and neck cancer: development and validation on a multi-centric MRI dataset.
    Radiother Oncol. 2023 Mar 31:109638. doi: 10.1016/j.radonc.2023.109638.
    >> Share

  97. MENECEUR S, Lock S, Gudziol V, Hering S, et al
    Corrigendum to "Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens" [Radiother. Oncol. 137 (2019) 24-31].
    Radiother Oncol. 2023;183:109619.
    >> Share

  98. S R MOHAMED A, Abusaif A, He R, Wahid K, et al
    Prospective validation of diffusion-weighted MRI as a biomarker of tumor response and oncologic outcomes in head and neck cancer: Results from an observational biomarker pre-qualification study.
    Radiother Oncol. 2023 Mar 27:109641. doi: 10.1016/j.radonc.2023.109641.
    >> Share

  99. LU ZJ, Liu T, Lin JY, Pei ST, et al
    Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Mar 22:109635. doi: 10.1016/j.radonc.2023.109635.
    >> Share

  100. ALY F, Ronn Hansen C, Al Mouiee D, Sundaresan P, et al
    Outcome prediction models incorporating clinical variables for Head and Neck Squamous cell Carcinoma: a systematic review of methodological conduct and risk of bias.
    Radiother Oncol. 2023 Mar 17:109629. doi: 10.1016/j.radonc.2023.109629.
    >> Share

  101. DUBEC MJ, Buckley DL, Berks M, Clough A, et al
    First-in-Human Technique Translation of Oxygen-Enhanced MRI to an MR Linac System in Patients with Head and Neck Cancer.
    Radiother Oncol. 2023 Mar 2:109592. doi: 10.1016/j.radonc.2023.109592.
    >> Share

  102. WU Z, Qi B, Lin FF, Zhang L, et al
    Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation.
    Radiother Oncol. 2023 Mar 2:109595. doi: 10.1016/j.radonc.2023.109595.
    >> Share

  103. WANG JH, Salama V, McCoy L, Dede C, et al
    Dysphagia and shortness-of-breath as markers for treatment failure and survival in oropharyngeal cancer after radiation.
    Radiother Oncol. 2023;180:109465.
    >> Share

    February 2023
  104. TAN W, Mao M, He H, Chen M, et al
    Endonasopharyngeal Ultrasound and Magnetic Resonance Imaging Features of Recurrent Retropharyngeal Nodes in Nasopharyngeal Carcinoma Patients: A Radiologic-histopathologic Study.
    Radiother Oncol. 2023 Feb 24:109579. doi: 10.1016/j.radonc.2023.109579.
    >> Share

  105. BOLLEN H, Willems S, Wegge M, Maes F, et al
    Benefits of automated gross tumor volume segmentation in head and neck cancer using multi-modality information.
    Radiother Oncol. 2023 Feb 21:109574. doi: 10.1016/j.radonc.2023.109574.
    >> Share

  106. ZHANG J, Lam SK, Teng X, Ma Z, et al
    Radiomic Feature Repeatability and Its Impact on Prognostic Model Generalizability: A Multi-Institutional Study on Nasopharyngeal Carcinoma Patients.
    Radiother Oncol. 2023 Feb 21:109578. doi: 10.1016/j.radonc.2023.109578.
    >> Share

  107. VALENTINI C, Ebert N, Koi L, Pfeifer M, et al
    Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models.
    Radiother Oncol. 2023 Feb 20:109546. doi: 10.1016/j.radonc.2023.109546.
    >> Share

  108. BEYAN C, Beyan E
    The prognosis may not be determined with the use of some pre-treatment complete blood count values in patients with non-metastatic nasopharyngeal carcinoma.
    Radiother Oncol. 2023 Feb 9:109529. doi: 10.1016/j.radonc.2023.109529.
    >> Share

  109. MAO JR, Lan KQ, Liu SL, Liu C, et al
    In reply to the Letter to the Editor by Cengiz Beyan and Esin Beyan regarding ''Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?".
    Radiother Oncol. 2023 Feb 9:109530. doi: 10.1016/j.radonc.2023.109530.
    >> Share

  110. PATRICIA KAPLAN L, Ivalu Sander Holm A, Grau Eriksen J, Heijmen BJM, et al
    Patient anatomy-specific trade-offs between sub-clinical disease coverage and normal tissue dose reduction in head-and-neck cancer.
    Radiother Oncol. 2023 Feb 8:109526. doi: 10.1016/j.radonc.2023.109526.
    >> Share

  111. GEHIN W, Lassalle B, Salleron J, Anxionnat R, et al
    DOSIMETRIC PREDICTIVE FACTORS FOR FACIAL NERVE PARALYSIS AFTER CYBERKNIFE(R) STEREOTACTIC RADIOTHERAPY FOR VESTIBULAR SCHWANNOMAS: A SINGLE INSTITUTION EXPERIENCE OF 88 PATIENTS.
    Radiother Oncol. 2023 Feb 1:109519. doi: 10.1016/j.radonc.2023.109519.
    >> Share

    January 2023
  112. YAO JJ, Jin YN, Zhang WJ, Zhang HY, et al
    Response to the letter by Dr Sari regarding the article "The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy".
    Radiother Oncol. 2023 Jan 31:109487. doi: 10.1016/j.radonc.2023.109487.
    >> Share

  113. TERZIDIS E, Friborg J, Vogelius I, Lelkaitis G, et al
    Tumor volume definitions in head and neck squamous cell carcinoma - comparing PET/MRI and histopathology.
    Radiother Oncol. 2023 Jan 20:109484. doi: 10.1016/j.radonc.2023.109484.
    >> Share

  114. YE X, Liu J, Quan R, Lu Y, et al
    DKK1 Affects Survival of Patients with Head and Neck Squamous Cell Carcinoma by Inducing Resistance to Radiotherapy and Immunotherapy.
    Radiother Oncol. 2023 Jan 20:109485. doi: 10.1016/j.radonc.2023.109485.
    >> Share

  115. LUO X, Liao W, He Y, Tang F, et al
    Deep learning-based accurate delineation of primary gross tumor volume of nasopharyngeal carcinoma on heterogeneous magnetic resonance imaging: a large-scale and multi-center study.
    Radiother Oncol. 2023 Jan 16:109480. doi: 10.1016/j.radonc.2023.109480.
    >> Share

  116. WANG X, Bai H, Li R, Wang L, et al
    High versus Standard Radiation Dose of Definitive Concurrent Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Radiother Oncol. 2023 Jan 12:109463. doi: 10.1016/j.radonc.2023.109463.
    >> Share

  117. LI Y, Sijtsema NM, de Vette SPM, Steenbakkers RJHM, et al
    Validation of the (18)F-FDG PET image biomarker model predicting late xerostomia after head and neck cancer radiotherapy.
    Radiother Oncol. 2023 Jan 3:109458. doi: 10.1016/j.radonc.2022.109458.
    >> Share

  118. GUEVORGUIAN P, Chinnery T, Lang P, Nichols A, et al
    External validation of a CT-based radiomics signature in oropharyngeal cancer: Assessing sources of variation.
    Radiother Oncol. 2023;178:109434.
    >> Share

    December 2022
  119. LEEUWENBERG AM, Reitsma JB, Bosch LVD, Hoogland J, et al
    The relation between prediction model performance measures and patient selection outcomes for proton therapy in head and neck cancer.
    Radiother Oncol. 2022 Dec 22:109449. doi: 10.1016/j.radonc.2022.109449.
    >> Share

  120. HUANG X, Zhuang M, Yang S, Wang Y, et al
    The valuable role of dynamic (18)F FDG PET/CT-derived kinetic parameter K(i) in patients with nasopharyngeal carcinoma prior to radiotherapy: a prospective study.
    Radiother Oncol. 2022 Dec 22:109440. doi: 10.1016/j.radonc.2022.109440.
    >> Share

  121. MAO JR, Lan KQ, Liu SL, Liu C, et al
    Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?
    Radiother Oncol. 2022 Dec 22:109445. doi: 10.1016/j.radonc.2022.109445.
    >> Share

  122. LIU Y, Zhang Y, Wang J, Huang X, et al
    Caudal distribution pattern of metastatic neck lymph nodes in nasopharyngeal carcinoma and prognostic significance of nodal spread distances.
    Radiother Oncol. 2022 Dec 19:109443. doi: 10.1016/j.radonc.2022.109443.
    >> Share

  123. ZHU GL, Zhang XM, Yang KB, Tang LL, et al
    Metastatic patterns of level II-V cervical lymph nodes assessed per vertebral levels in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Dec 19:109447. doi: 10.1016/j.radonc.2022.109447.
    >> Share

  124. ZENG GP, Sun R, Zhao Z
    Letter to the editor regarding "The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6mm in head and neck squamous cell carcinoma: Significant acute and late toxicity reduction".
    Radiother Oncol. 2022 Dec 14:109442. doi: 10.1016/j.radonc.2022.109442.
    >> Share

  125. HU YJ, Lu TZ, Guo QJ, Zhang L, et al
    The role of radiologic extranodal extension in predicting prognosis and chemotherapy benefit for T1-2N1 nasopharyngeal carcinoma: a multicenter retrospective study.
    Radiother Oncol. 2022 Dec 1:S0167-8140(22)04582.
    >> Share

  126. DE FELICE F, Cirillo A, Botticelli A
    Ideal regimen for induction chemotherapy in nasopharyngeal cancer: Still a hot issue?
    Radiother Oncol. 2022;177:111-112.
    >> Share

    November 2022
  127. CHEN WY, Lu SH, Wang YM, Wang CW, et al
    Post-irradiation Sarcoma after Definitive Radiation Therapy for Nasopharyngeal Carcinoma.
    Radiother Oncol. 2022 Nov 23:S0167-8140(22)04560.
    >> Share

  128. LIU ZC, Zeng KH, Gu ZB, Chen RP, et al
    Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage Nasopharyngeal Carcinoma based on propensity score-matching.
    Radiother Oncol. 2022 Nov 18:S0167-8140(22)04554.
    >> Share

  129. WANG G, Huang C, Yang K, Guo R, et al
    Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04548.
    >> Share

  130. YAO JJ, Jin YN, Lin YJ, Zhang WJ, et al
    The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04547.
    >> Share

  131. BIN Y, Meng Z, Huang LL, Hu XY, et al
    Prognostic value of the cervical lymph node necrosis ratio in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Nov 11. pii: S0167-8140(22)04549.
    >> Share

  132. TAKADA A, Ichikawa Y, Nakamura S, Toyomasu Y, et al
    Preliminary results of reduced myocardial blood flow in the subacute phase after radiation therapy for thoracic esophageal cancer: A quantitative analysis with stress dynamic myocardial computed tomography perfusion imaging.
    Radiother Oncol. 2022 Nov 10. pii: S0167-8140(22)04546.
    >> Share

  133. ZHONG Z, Wang D, Liu Y, Shao S, et al
    Lymph Drainage and Cervical Fascia Anatomy-Oriented Differential Nodal CTV Delineation at the Supraclavicular Region for Esophageal Cancer and Nasopharyngeal Cancer.
    Radiother Oncol. 2022 Nov 3. pii: S0167-8140(22)04531.
    >> Share

  134. CHOW JCH, Lui JCF, Cheung KM, Tam AHP, et al
    Post-radiation primary hypothyroidism in patients with head and neck cancer: External validation of thyroid gland dose-volume constraints with long-term endocrine outcomes.
    Radiother Oncol. 2022 Nov 3. pii: S0167-8140(22)04529.
    >> Share

  135. HUANG H, Miao J, Zhao C, Wang L, et al
    Response to Gargi S Sarode, Sachin C Sarode, and Rahul Anand's Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing inten
    Radiother Oncol. 2022 Nov 2. pii: S0167-8140(22)04517.
    >> Share

  136. SARODE GS, Sarode SC, Anand R
    Letter to the Editor of Radiotherapy and Oncology regarding the paper titled "Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective pha
    Radiother Oncol. 2022 Nov 2. pii: S0167-8140(22)04515.
    >> Share

  137. LEE CT, Litwin S, Yao CMKL, Liu JC, et al
    Osteoradionecrosis rate in oropharynx cancer treated with dose volume histogram based constraints.
    Radiother Oncol. 2022;176:215-221.
    >> Share

  138. VAN DER WEIJST L, Azria D, Berkovic P, Boisselier P, et al
    The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study.
    Radiother Oncol. 2022;176:127-137.
    >> Share

    October 2022
  139. ROESCH J, Oertel M, Wegen S, Trommer M, et al
    Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis.
    Radiother Oncol. 2022 Oct 20. pii: S0167-8140(22)04502.
    >> Share

  140. TIEN CT, Chen CN, Young YH
    Post-irradiation endolymphatic hydrops vs. post-irradiation sudden deafness.
    Radiother Oncol. 2022 Oct 17. pii: S0167-8140(22)04504.
    >> Share

  141. RONN HANSEN C, Price G, Field M, Sarup N, et al
    Larynx cancer survival model developed through open-source federated learning.
    Radiother Oncol. 2022 Oct 5. pii: S0167-8140(22)04493.
    >> Share

    September 2022
  142. NADERI E, Schack LMH, Welsh C, Sim AYL, et al
    Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer.
    Radiother Oncol. 2022 Sep 30. pii: S0167-8140(22)04486.
    >> Share

  143. HUMBERT-VIDAN L, Hansen CR, Fuller CD, Petit S, et al
    Protocol Letter: A multi-institutional retrospective case-control cohort investigating PREDiction models for Mandibular OsteoRadioNecrosis in head and neck cancer (PREDMORN).
    Radiother Oncol. 2022 Sep 27. pii: S0167-8140(22)04473.
    >> Share

  144. DRAGUET C, Barragan-Montero AM, Chocan Vera M, Thomas M, et al
    Automated clinical decision support system with deep learning dose prediction and NTCP models to evaluate treatment complications in patients with esophageal cancer.
    Radiother Oncol. 2022 Sep 24. pii: S0167-8140(22)04263.
    >> Share

  145. OUD M, Breedveld S, Gizynska M, Kroesen M, et al
    An online adaptive plan library approach for intensity modulated proton therapy for head and neck cancer.
    Radiother Oncol. 2022 Sep 20. pii: S0167-8140(22)04278.
    >> Share

    August 2022
  146. DE ROEST RH, van der Heijden M, W R Wesseling F, de Ruiter EJ, et al
    Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
    Radiother Oncol. 2022 Aug 13. pii: S0167-8140(22)04234.
    >> Share

  147. ZHANG Y, Alshaikhi J, Amos RA, Lowe M, et al
    Improving workflow for adaptive proton therapy with predictive anatomical modelling: A proof of concept.
    Radiother Oncol. 2022;173:93-101.
    >> Share

    July 2022
  148. GHATASHEH H, Hui Huang S, Su J, Xu W, et al
    Evaluation of risk-tailored individualized selection of radiation therapy target volume for Head and Neck Carcinoma of Unknown Primary.
    Radiother Oncol. 2022 Jul 26. pii: S0167-8140(22)04214.
    >> Share

  149. HABRICH J, Boeke S, Nachbar M, Nikolaou K, et al
    Repeatability of diffusion-weighted magnetic resonance imaging in head and neck cancer at a 1.5 T MR-Linac.
    Radiother Oncol. 2022 Jul 25. pii: S0167-8140(22)04218.
    >> Share

  150. HUANG H, Miao J, Xiao X, Hu J, et al
    Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): a prospective phase II randomized controlled study.
    Radiother Oncol. 2022 Jul 8. pii: S0167-8140(22)04191.
    >> Share

  151. PRICE JM, West CM, Dixon LM, Iyizoba-Ebozue Z, et al
    Similar long-term swallowing outcomes for accelerated, mildly-hypofractionated radiotherapy compared to conventional fractionation in oropharyngeal cancer: A multi-centre study.
    Radiother Oncol. 2022;172:111-117.
    >> Share

    June 2022
  152. QIAN D, Chen X, Shang X, Wang Y, et al
    Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II rando
    Radiother Oncol. 2022 Jun 25. pii: S0167-8140(22)04176.
    >> Share

  153. KROESE TE, Christ SM, van Rossum PSN, Burger MDL, et al
    Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study.
    Radiother Oncol. 2022 Jun 23. pii: S0167-8140(22)04173.
    >> Share

  154. GONG J, Zhang W, Huang W, Liao Y, et al
    CT-based radiomics nomogram may predict local recurrence-free survival in esophageal cancer patients receiving definitive chemoradiation or radiotherapy: a multicenter study.
    Radiother Oncol. 2022 Jun 21. pii: S0167-8140(22)04171.
    >> Share

  155. HANSEN CR, Price G, Field M, Sarup N, et al
    Open-source distributed learning validation for a larynx cancer survival model following radiotherapy.
    Radiother Oncol. 2022 Jun 20. pii: S0167-8140(22)04170.
    >> Share

  156. FU G, Xie Y, Pan J, Qiu Y, et al
    Longitudinal study of irradiation-induced brain functional network alterations in patients with nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Jun 16. pii: S0167-8140(22)04164.
    >> Share

  157. SCHOONBEEK RC, Festen S, van der Laan BFAM, Plaat BEC, et al
    The effect of delayed treatment initiation on adverse events and recurrence in older head and neck cancer patients.
    Radiother Oncol. 2022 Jun 6. pii: S0167-8140(22)04146.
    >> Share

  158. MASSACCESI M, Dinapoli N, Fuga V, Rupe C, et al
    A predictive nomogram for trismus after radiotherapy for head and neck cancer.
    Radiother Oncol. 2022 Jun 2. pii: S0167-8140(22)04137.
    >> Share

    May 2022
  159. LIU Z, Luo Y, Guo R, Yang B, et al
    Head and Neck Radiotherapy Causes Significant Disruptions of Cochlear Ribbon Synapses and Consequent Sensorineural Hearing Loss.
    Radiother Oncol. 2022 May 28. pii: S0167-8140(22)02279.
    >> Share

  160. ZHAO DW, Fan WJ, Fang XM, Luo YR, et al
    Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging.
    Radiother Oncol. 2022 May 15. pii: S0167-8140(22)00251.
    >> Share

  161. YI-LIANG SHEN E, Hung TM, Tsan DL, Cheng NM, et al
    Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating epstein-barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
    Radiother Oncol. 2022 May 11. pii: S0167-8140(22)00240.
    >> Share

    April 2022
  162. ZHAO Y, Liao X, Wang Y, Lan W, et al
    Level Ib CTV delineation in nasopharyngeal carcinoma based on lymph node distribution and topographic anatomy.
    Radiother Oncol. 2022 Apr 29. pii: S0167-8140(22)00232.
    >> Share

  163. DOHOPOLSKI M, Wang K, Morgan H, Sher D, et al
    Predicting the need for aggressive nutritional supplementation in head and neck cancer patients receiving radiation therapy.
    Radiother Oncol. 2022 Apr 21. pii: S0167-8140(22)00224.
    >> Share

  164. SHEN H, Yin J, Niu R, Lian Y, et al
    Development and validation of a radiomic nomogram to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carc
    Radiother Oncol. 2022 Apr 21. pii: S0167-8140(22)00222.
    >> Share

  165. LEE BM, Lee CG
    Significance of mid-radiotherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography in esophageal cancer.
    Radiother Oncol. 2022 Apr 18. pii: S0167-8140(22)00191.
    >> Share

  166. WELZ S, Paulsen F, Pfannenberg C, Reimold M, et al
    Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [(18)F]FMISO PET/CT.
    Radiother Oncol. 2022 Apr 5. pii: S0167-8140(22)00170.
    >> Share

  167. JENSEN KH, Vogelius IR, Bernsdorf M, Gothelf A, et al
    Early non-cancer mortality risk prediction after curative-intent radiotherapy or chemoradiotherapy for head and neck squamous cell carcinoma.
    Radiother Oncol. 2022 Apr 5. pii: S0167-8140(22)00169.
    >> Share

  168. LUDWIG R, Hoffmann JM, Pouymayou B, Dappen MB, et al
    Detailed patient-individual reporting of lymph node involvement in oropharyngeal squamous cell carcinoma with an online interface.
    Radiother Oncol. 2022;169:1-7.
    >> Share

    March 2022
  169. YUE M, Xue X, Wang Z, Lambo RL, et al
    Dose prediction via distance-guided deep learning: initial development for nasopharyngeal carcinoma radiotherapy.
    Radiother Oncol. 2022 Mar 26. pii: S0167-8140(22)00150.
    >> Share

  170. BORDERIAS-VILLARROEL E, Taasti V, Van Elmpt W, Teruel-Rivas S, et al
    Evaluation of the clinical value of automatic online dose restoration for adaptive proton therapy of head and neck cancer.
    Radiother Oncol. 2022 Mar 25. pii: S0167-8140(22)00149.
    >> Share

  171. KARAVOLIA E, van Rijn-Dekker MI, Van den Bosch L, van den Hoek JGM, et al
    Impact of sarcopenia on acute radiation-induced toxicity in head and neck cancer patients.
    Radiother Oncol. 2022 Mar 15. pii: S0167-8140(22)00145.
    >> Share

  172. ZHOU X, Wang W, Zhou C, Zhu J, et al
    Long-term outcomes of replanning during intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma: An updated and expanded retrospective analysis.
    Radiother Oncol. 2022 Mar 11. pii: S0167-8140(22)00132.
    >> Share

  173. HUANG CC, Lai YR, Chiu WC, Fang FM, et al
    Concurrent chemoradiation therapy is associated with an accelerated risk of cardiovascular autonomic dysfunction in patients with nasopharyngeal carcinoma: A 9-year prospective follow-up study.
    Radiother Oncol. 2022 Mar 11. pii: S0167-8140(22)00129.
    >> Share

  174. CHOW R, Simone CB 2nd
    Radiation induced lymphopenia in head and neck cancer: The importance of rigorous statistical analysis, radiation field size, and treatment modality.
    Radiother Oncol. 2022 Mar 10. pii: S0167-8140(22)00112.
    >> Share

  175. DAI D, Tian Q, Shui Y, Li J, et al
    Response to "Radiation induced lymphopenia in head and neck cancer: The importance of rigorous statistical analysis, radiation field size, and treatment modality".
    Radiother Oncol. 2022 Mar 10. pii: S0167-8140(22)00109.
    >> Share

  176. NACHANKAR A, Musha A, Kubo N, Kawamura H, et al
    Dosimetric analysis of intraocular hemorrhage in nonsquamous head and neck cancers treated with carbon-ion radiotherapy.
    Radiother Oncol. 2022 Mar 4. pii: S0167-8140(22)00118.
    >> Share

  177. GORPHE P, Classe M, Ammari S, Garcia G, et al
    Patterns of disease events and causes of death in patients with HPV-positive versus HPV-negative oropharyngeal carcinoma.
    Radiother Oncol. 2022;168:40-45.
    >> Share

    February 2022
  178. LASKAR SG, Sinha S, Pai DP, Nair D, et al
    Definitive and adjuvant radiation therapy for external auditory canal and temporal bone squamous cell carcinomas: Long term outcomes.
    Radiother Oncol. 2022 Feb 24. pii: S0167-8140(22)00106.
    >> Share

  179. BONOMO P, Desideri I, Mangoni M, Saieva C, et al
    Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: a phase 1/2 trial.
    Radiother Oncol. 2022 Feb 11. pii: S0167-8140(22)00091.
    >> Share

  180. SCANDURRA D, Meijer TWH, Free J, van den Hoek JGM, et al
    Evaluation of robustly optimised intensity modulated proton therapy for nasopharyngeal carcinoma.
    Radiother Oncol. 2022 Feb 5. pii: S0167-8140(22)00080.
    >> Share

  181. PAN D, Rong X, Zhu Y, Ng WT, et al
    A novel nomogram to predict overall survival in head and neck cancer survivors with radiation-induced brain necrosis.
    Radiother Oncol. 2022 Feb 1. pii: S0167-8140(22)00060.
    >> Share

    January 2022
  182. SUN XS, Zhu MY, Wen DX, Luo DH, et al
    Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in local recurrence nasopharyngeal carcinoma patients.
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00028.
    >> Share

  183. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Head and neck cancer diagnoses and faster treatment initiation during COVID-19: correspondence.
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00026.
    >> Share

  184. SCHOONBEEK RC, de Jel DVC, van Dijk BAC, Willems SM, et al
    Response to "Head and neck cancer diagnoses and faster treatment initiation during COVID-19: Correspondence".
    Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00033.
    >> Share

  185. CHATTERJEE S, Maulik S, Prasath S, Arun B, et al
    Xerostomia quality of life and resource requirements following parotid sparing adaptive radiotherapy in head and neck cancers: Results of a prospective cohort study (Study ID CTRI/2017/11/010683).
    Radiother Oncol. 2022 Jan 27. pii: S0167-8140(22)00024.
    >> Share

  186. ZECH HB, Berger J, Mansour WY, Nordquist L, et al
    Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer.
    Radiother Oncol. 2022 Jan 27. pii: S0167-8140(22)00022.
    >> Share

  187. AL-MAMGANI A, Kessels R, Janssen T, Navran A, et al
    The dosimetric and clinical advantages of the GTV-CTV-PTV margins reduction by 6mm in head and neck squamous cell carcinoma: significant acute and late toxicity reduction.
    Radiother Oncol. 2022 Jan 20. pii: S0167-8140(22)00017.
    >> Share

  188. HE J, Qian L, Gao J
    Comment on ''Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)".
    Radiother Oncol. 2022 Jan 19. pii: S0167-8140(22)00005.
    >> Share

  189. ROBIJNS J, Lodewijckx J, Claes S, Van Bever L, et al
    Response to the Comment on ''Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)"by He et al.
    Radiother Oncol. 2022 Jan 19. pii: S0167-8140(22)00006.
    >> Share

  190. DAI D, Tian Q, Shui Y, Li J, et al
    The impact of radiation induced lymphopenia in the prognosis of head and neck cancer: A systematic review and meta-analysis.
    Radiother Oncol. 2022 Jan 8. pii: S0167-8140(22)00007.
    >> Share

  191. HUANG W, Zhang Q, Wu G, Chen P, et al
    Corrigendum to "DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1alpha, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients" [Radiother Oncol (2021) 164:146-154].
    Radiother Oncol. 2022 Jan 7. pii: S0167-8140(21)09059.
    >> Share

  192. LIU T, Shen BW, Liu LT, Yang ZC, et al
    Impact of salvage radiotherapy on survival of patients with advanced locally recurrent nasopharyngeal carcinoma: Derivation and validation of a predictive model.
    Radiother Oncol. 2022 Jan 5. pii: S0167-8140(21)09094.
    >> Share

  193. FORNER LE, Dieleman FJ, Shaw RJ, Kanatas A, et al
    Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1.
    Radiother Oncol. 2022;166:137-144.
    >> Share

    December 2021
  194. GUO Q, Xiao N, Xu H, Zong J, et al
    Rationality of the international guideline's recommendation regarding selective coverage of level Ib in clinical target volume with nasopharyngeal carcinoma: Results from a real-world series.
    Radiother Oncol. 2021 Dec 29. pii: S0167-8140(21)09081.
    >> Share

  195. TANG SQ, Chen L, Li WF, Chan ATC, et al
    Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9,468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.
    Radiother Oncol. 2021 Dec 28. pii: S0167-8140(21)09077.
    >> Share

  196. SCHOONBEEK RC, de Jel DVC, van Dijk BAC, Willems SM, et al
    Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: a nationwide population-based analysis.
    Radiother Oncol. 2021 Dec 13. pii: S0167-8140(21)09049.
    >> Share

  197. MUSHA A, Hirai C, Kitada Y, Tsunoda A, et al
    Relationship between oral mucositis and the oral bacterial count in patients with head and neck cancer undergoing carbon ion radiotherapy: A prospective study.
    Radiother Oncol. 2021 Dec 10. pii: S0167-8140(21)09054.
    >> Share

  198. BEUKEMA JC, de Groot C, Plukker JTM, Vliegenthart R, et al
    Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: a prospective cross-sectional pilot study.
    Radiother Oncol. 2021 Dec 2. pii: S0167-8140(21)09025.
    >> Share

    November 2021
  199. KUTZ LM, Abel J, Schweizer D, Tribius S, et al
    Quality of life, HPV-status and phase angle predict survival in head and neck cancer patients under (chemo)radiotherapy undergoing nutritional intervention: Results from the prospective randomized HEADNUT-trial.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09004.
    >> Share

  200. JIN YN, Yang QQ, Li ZQ, Ou XQ, et al
    Development of a Web-based Prognostic Model to Quantify the Survival Benefit of Cumulative Cisplatin Dose during Concurrent Chemoradiotherapy in Childhood Nasopharyngeal Carcinoma.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09008.
    >> Share

  201. NISHIBUCHI I, Murakami Y, Kubo K, Imano N, et al
    Temporal Changes and Risk Factors for Esophageal Stenosis after Salvage Radiotherapy in Superficial Esophageal Cancer following Non-Curative Endoscopic Submucosal Dissection.
    Radiother Oncol. 2021 Nov 25. pii: S0167-8140(21)09007.
    >> Share

  202. PATEL V, Kwok J, Burke M, Urbano TG, et al
    Should the HPV positive oropharyngeal cancer patient be considered for a two-stage dental assessment for their radiation treatment?
    Radiother Oncol. 2021;164:232-235.
    >> Share

  203. GAWRYSZUK A, Bijl HP, van der Schaaf A, Perdok N, et al
    Relationship between videofluoroscopic and subjective (physician- and patient- rated) assessment of late swallowing dysfunction after (chemo) radiation: Results of a prospective observational study.
    Radiother Oncol. 2021;164:253-260.
    >> Share

    October 2021
  204. BROOKER RC, Antczak P, Liloglou T, Risk JM, et al
    Genetic variants associated with mandibular osteoradionecrosis following radiotherapy for head and neck malignancy.
    Radiother Oncol. 2021;165:87-93.
    >> Share

  205. CHIN O, Yu E, O'Sullivan B, Su J, et al
    Prognostic Importance of Radiologic Extranodal Extension in Nasopharyngeal Carcinoma Treated in a Canadian Cohort.
    Radiother Oncol. 2021 Oct 27. pii: S0167-8140(21)08785.
    >> Share

  206. ZHANG ZM, Zhao R, Bao Y, Zhou LX, et al
    A novel technique of endonasopharyngeal ultrasound-guided transnasopharyngeal needle aspiration in the diagnosis of submucosal recurrence of nasopharyngeal carcinoma after chemoradiotherapy.
    Radiother Oncol. 2021 Oct 7. pii: S0167-8140(21)08758.
    >> Share

  207. SHI Z, Zhu X, Ke S, Qiu H, et al
    Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses.
    Radiother Oncol. 2021 Oct 7. pii: S0167-8140(21)08754.
    >> Share

  208. YAN A, Hanna A, Wilson TG, Deraniyagala R, et al
    Correlation between tumor voxel dose response matrix and tumor biomarker profile in patients with head and neck squamous cell carcinoma.
    Radiother Oncol. 2021 Oct 4. pii: S0167-8140(21)08748.
    >> Share

  209. KANEHIRA T, van Kranen S, Jansen T, Hamming-Vrieze O, et al
    Comparisons of normal tissue complication probability models derived from planned and delivered dose for head and neck cancer patients.
    Radiother Oncol. 2021 Oct 4. pii: S0167-8140(21)06738.
    >> Share

    September 2021
  210. HUANG W, Zhang Q, Wu G, Pian Chen P, et al
    DCE-MRI quantitative transport mapping for noninvasively detecting hypoxia inducible factor-1alpha, epidermal growth factor receptor overexpression, and Ki-67 in nasopharyngeal carcinoma patients.
    Radiother Oncol. 2021 Sep 27. pii: S0167-8140(21)06739.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016